ALDER BIOPHARMACEUTICALS INC

April 18, 2018 .
Issuer
ALDER BIOPHARMACEUTICALS INC ALDR
Reporting Owner
Lavelle Erin [ Officer, Chief Commercial Officer, ]
Signed By
Erin Lavelle
Preview. View filing ...
4
0001209191-18-025410.nc XML (1)
Ownership: Statement of changes in beneficial ownership. Insider trading ( Directors, Officers, Significant Shareholders )
Period of report
April 16, 2018
Stock Option (Right to Buy)
[A : Grant / award] 300,000 shares x $0.00/sh Total owned: 300,000 [ Underlying Securities: Common Stock ] 300,000 shares
April 18, 2018 .
Issuer
ALDER BIOPHARMACEUTICALS INC ALDR
Reporting Owner
Lavelle Erin [ Officer, Chief Commercial Officer, ]
Signed By
Erin Lavelle
Preview. View filing ...
3
0001209191-18-025405.nc XML (1)
Ownership: Initial statement of beneficial ownership of securities. Insider trading ( Directors, Officers, Significant Shareholders )
Period of report
April 16, 2018
No securities are beneficially owned.
Total owned: 0
April 16, 2018 .
Filer
ALDER BIOPHARMACEUTICALS INC
Preview. View filing ...
8-K
0001193125-18-117875.nc
Current report Includes: Material events, Director, Executive officer elections resignations, departures, Financial disclosures, Changes in control, etc.
Item
5.02 Governance: Departure/Appointment/Compensation Directors and Officers
Period of report
April 16, 2018
March 27, 2018 .
Issuer
ALDER BIOPHARMACEUTICALS INC ALDR
Reporting Owner
Cleveland Paul B [ Director, Officer, Interim President and CEO, ]
Signed By
Paul B Cleveland
Preview. View filing ...
4
0001209191-18-021826.nc XML (1)
Ownership: Statement of changes in beneficial ownership. Insider trading ( Directors, Officers, Significant Shareholders )
Period of report
March 26, 2018
Stock Option (Right to Buy)
[A : Grant / award] 100,000 shares x $0.00/sh Total owned: 100,000 [ Underlying Securities: Common Stock ] 100,000 shares
March 23, 2018 .
Filed By
Redmile Group, LLC
Subject Company
ALDER BIOPHARMACEUTICALS INC
Preview. View filing ...
SC 13D
0001425738-18-000020.nc
Acquisition of beneficial ownership of 5% or more of any class of equity securities. Includes: Buy / Acquire / Sell / Dispose 1% or more. Incl: Takeovers, change of control
March 20, 2018 .
Filer
ALDER BIOPHARMACEUTICALS INC
Preview. View filing ...
8-K
0001193125-18-089221.nc
Current report Includes: Material events, Director, Executive officer elections resignations, departures, Financial disclosures, Changes in control, etc.
Item
5.02 Governance: Departure/Appointment/Compensation Directors and Officers
Period of report
March 15, 2018
Feb. 26, 2018 .
Filer
ALDER BIOPHARMACEUTICALS INC
Preview. View filing ...
10-K ALDR 
0001564590-18-003221.nc XBRL XML (6)
Annual report ( Financial statements and condition ) ( Risk ) ( Corporate Governance ) ( Executive compensation ) ( Management Discussion Analysis MDA MD&A )
Focus Period
2017 : FY
Fiscal year ends
--12-31
Period of report
Dec. 31, 2017
Financials (experimental)
In USD 3 mo ending 2017-12-31 3 mo ending 2016-12-31 12 mo ending 2017-12-31 12 mo ending 2016-12-31 12 mo ending 2015-12-31
Revenues  936,000    1,600,000  100,000  
Net Income  -54,357,000  -48,891,000  -288,879,008  -156,254,000  -85,470,000
EPS Diluted  -0.80  -0.97  -4.95  -3.23  -2.11
EPS Basic  -0.80  -0.97  -4.95  -3.23  -2.11
Feb. 26, 2018 .
Filer
ALDER BIOPHARMACEUTICALS INC
Preview. View filing ...
S-8
0001193125-18-058601.nc
Initial registration statement for securities to be offered to employees : employee benefit plans
Feb. 26, 2018 .
Filer
ALDER BIOPHARMACEUTICALS INC
Preview. View filing ...
8-K
0001564590-18-003246.nc
Current report Includes: Material events, Director, Executive officer elections resignations, departures, Financial disclosures, Changes in control, etc.
Item
2.02 Financial: Results of Operations and Financial Condition
9.01 Financial Statements and Exhibits
Period of report
Feb. 26, 2018
1 month, 4 weeks ago ...
Filer
ALDER BIOPHARMACEUTICALS INC
Preview. View filing ...
8-K
0001193125-18-056118.nc
Current report Includes: Material events, Director, Executive officer elections resignations, departures, Financial disclosures, Changes in control, etc.
Item
5.02 Governance: Departure/Appointment/Compensation Directors and Officers
Period of report
Feb. 17, 2018
Feb. 21, 2018 .
Issuer
ALDER BIOPHARMACEUTICALS INC ALDR
Reporting Owner
Litton Mark James [ Officer, Chief Business Officer, ]
Signed By
Mark J Litton
Preview. View filing ...
4
0001209191-18-012036.nc XML (1)
Ownership: Statement of changes in beneficial ownership. Insider trading ( Directors, Officers, Significant Shareholders )
Period of report
Feb. 16, 2018
Stock Option (Right to Buy)
[A : Grant / award] 75,000 shares x $0.00/sh Total owned: 75,000 [ Underlying Securities: Common Stock ] 75,000 shares
Feb. 21, 2018 .
Issuer
ALDER BIOPHARMACEUTICALS INC ALDR
Reporting Owner
Bucher James B [ Officer, Sr. VP & General Counsel, ]
Signed By
James B Bucher
Preview. View filing ...
4
0001209191-18-012055.nc XML (1)
Ownership: Statement of changes in beneficial ownership. Insider trading ( Directors, Officers, Significant Shareholders )
Period of report
Feb. 16, 2018
Stock Option (Right to Buy)
[A : Grant / award] 70,000 shares x $0.00/sh Total owned: 70,000 [ Underlying Securities: Common Stock ] 70,000 shares
Feb. 21, 2018 .
Issuer
ALDER BIOPHARMACEUTICALS INC ALDR
Reporting Owner
Schatzman Randall C [ Director, Officer, President and CEO, ]
Signed By
Randall Schatzman
Preview. View filing ...
4
0001209191-18-012043.nc XML (1)
Ownership: Statement of changes in beneficial ownership. Insider trading ( Directors, Officers, Significant Shareholders )
Period of report
Feb. 16, 2018
Stock Option (Right to Buy)
[A : Grant / award] 200,000 shares x $0.00/sh Total owned: 200,000 [ Underlying Securities: Common Stock ] 200,000 shares
Feb. 21, 2018 .
Issuer
ALDER BIOPHARMACEUTICALS INC ALDR
Reporting Owner
Sandoval Elisabeth [ Officer, CCO & EVP, Corporate Strategy, ]
Signed By
Elisabeth A Sandoval
Preview. View filing ...
4
0001209191-18-012047.nc XML (1)
Ownership: Statement of changes in beneficial ownership. Insider trading ( Directors, Officers, Significant Shareholders )
Period of report
Feb. 16, 2018
Stock Option (Right to Buy)
[A : Grant / award] 60,000 shares x $0.00/sh Total owned: 60,000 [ Underlying Securities: Common Stock ] 60,000 shares
Feb. 21, 2018 .
Issuer
ALDER BIOPHARMACEUTICALS INC ALDR
Reporting Owner
Latham John A [ Officer, Chief Scientific Officer, ]
Signed By
John A Latham
Preview. View filing ...
4
0001209191-18-012045.nc XML (1)
Ownership: Statement of changes in beneficial ownership. Insider trading ( Directors, Officers, Significant Shareholders )
Period of report
Feb. 16, 2018
Stock Option (Right to Buy)
[A : Grant / award] 60,000 shares x $0.00/sh Total owned: 60,000 [ Underlying Securities: Common Stock ] 60,000 shares
Feb. 21, 2018 .
Issuer
ALDER BIOPHARMACEUTICALS INC ALDR
Reporting Owner
Hassler Randal [ Officer, EVP, Pharmaceutical Ops., ]
Signed By
Randal Hassler
Preview. View filing ...
4
0001209191-18-012038.nc XML (1)
Ownership: Statement of changes in beneficial ownership. Insider trading ( Directors, Officers, Significant Shareholders )
Period of report
Feb. 16, 2018
Stock Option (Right to Buy)
[A : Grant / award] 80,000 shares x $0.00/sh Total owned: 80,000 [ Underlying Securities: Common Stock ] 80,000 shares
Feb. 21, 2018 .
Issuer
ALDER BIOPHARMACEUTICALS INC ALDR
Reporting Owner
Smith Jeffrey T L [ Officer, Managing Director, ]
Signed By
Jeffrey T L Smith
Preview. View filing ...
4
0001209191-18-012041.nc XML (1)
Ownership: Statement of changes in beneficial ownership. Insider trading ( Directors, Officers, Significant Shareholders )
Period of report
Feb. 16, 2018
Stock Option (Right to Buy)
[A : Grant / award] 60,000 shares x $0.00/sh Total owned: 60,000 [ Underlying Securities: Common Stock ] 60,000 shares
Feb. 21, 2018 .
Issuer
ALDER BIOPHARMACEUTICALS INC ALDR
Reporting Owner
Benedict Larry [ Officer, EVP and PAO, ]
Signed By
Larry Benedict
Preview. View filing ...
4
0001209191-18-012049.nc XML (1)
Ownership: Statement of changes in beneficial ownership. Insider trading ( Directors, Officers, Significant Shareholders )
Period of report
Feb. 16, 2018
Stock Option (Right to Buy)
[A : Grant / award] 60,000 shares x $0.00/sh Total owned: 60,000 [ Underlying Securities: Common Stock ] 60,000 shares
Preview. View filing ...
SC 13G/A
0001144204-18-008966.nc
Schedule filed to report acquisition of beneficial ownership of 5% or more of a class of equity securities by passive investors and institutions
Feb. 14, 2018 .
Filed By
Redmile Group, LLC
Subject Company
ALDER BIOPHARMACEUTICALS INC
Preview. View filing ...
SC 13G/A
0001425738-18-000002.nc
Schedule filed to report acquisition of beneficial ownership of 5% or more of a class of equity securities by passive investors and institutions
db